



**HAL**  
open science

## **Efficacy of passive immunization in broiler chicks via an inactivated *Escherichia coli* autogenous vaccine administered to broiler breeder hens**

Alassane Keita, Laetitia Le Devendec, Michel Amelot, Julie Puterflam, Camille Lucas, Stéphanie Bougeard, Sabine Delannoy, Catherine Schouler, Patrick Fach, Pierrick Lucas, et al.

### ► To cite this version:

Alassane Keita, Laetitia Le Devendec, Michel Amelot, Julie Puterflam, Camille Lucas, et al.. Efficacy of passive immunization in broiler chicks via an inactivated *Escherichia coli* autogenous vaccine administered to broiler breeder hens. *Avian Pathology*, 2022, 51 (5), pp.445-456. 10.1080/03079457.2022.2084362 . hal-03700012

**HAL Id: hal-03700012**

**<https://hal.inrae.fr/hal-03700012>**

Submitted on 20 Jun 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

1 **Efficacy of passive immunization in broiler chicks via an inactivated *Escherichia***  
2 ***coli* autogenous vaccine administered to broiler breeder hens**

3 Alassane Keita<sup>a\*</sup>, Laetitia Le Devendec<sup>a</sup>, Michel Amelot<sup>a</sup>, Julie Puterflam<sup>b</sup>, Camille Lucas<sup>a</sup>, Stéphanie  
4 Bougeard<sup>a</sup>, Sabine Delannoy<sup>c</sup>, Catherine Schouler<sup>d</sup>, Patrick Fach<sup>c</sup>, Pierrick Lucas<sup>a</sup>, Rozenn Souillard<sup>a</sup> and  
5 Isabelle Kempf<sup>a</sup>

6

7 <sup>a</sup>Ploufragan-Plouzané-Niort Laboratory, Zoopôle les croix, 22440 Ploufragan, France ; <sup>b</sup>ITAVI, 22440  
8 Ploufragan, France ; <sup>c</sup>ANSES – French Agency for Food, Environmental and Occupational Health and  
9 Safety Food Research Laboratory, Platform IdentityPath, 94700 Maisons-Alfort, France; <sup>d</sup>INRAE,  
10 Université de Tours, ISP, 37380, Nouzilly, France

11 Corresponding author: [alassane.keita@anses.fr](mailto:alassane.keita@anses.fr)

12

13 **ABSTRACT**

14 Avian pathogenic *Escherichia coli* (APEC) cause extra-intestinal infections called colibacillosis, which is  
15 the dominant bacterial disease in broilers. To date, given the diversity of APEC strains and the need for  
16 an acceptable level of protection in day-old chicks (DOCs), no satisfactory commercial vaccine is  
17 available. As part of a French nationwide project, we selected three representative strains among  
18 several hundred APEC that cause colibacillosis disease. We first performed experiments to develop  
19 colibacillosis *in vivo* models, using an inoculum of  $3 \times 10^7$  CFU of each *E. coli* strain per chick. Two APEC  
20 strains (19-381 and 19-383-M1) were found to be highly virulent for DOCs, whereas the third strain  
21 (19-385-M1) induced no mortality nor morbidity.

22 We then produced an autogenous vaccine using the 19-381 and 19-383-M1 APEC strains and a passive  
23 immunization trial was undertaken. Specific-pathogen-free Leghorn hens were vaccinated twice two  
24 weeks apart, the control group receiving a saline solution. The vaccinated and control hens exhibited  
25 no clinical signs and egg production and fertility of both groups were similar. Fertile eggs were collected  
26 for two weeks after the second vaccination and DOCs were obtained. After challenge with each APEC  
27 (19-381 and 19-383-M1), DOCs appeared to be partially protected from infection with the 19-383-M1  
28 strain, with 40% mortality instead of 80% for the non-vaccinated chicks. No protection was found when  
29 the chicks were challenged with the 19-381 strain. Now, further work is needed to consider some  
30 aspects: severity of the pathogen model, persistence of the protection, number of APEC strains in the  
31 autogenous vaccine, choice of adjuvants and heterologous protection of the vaccine made from strain  
32 19-383-M1.

33

34

35

36

37

38

39 **RESEARCH HIGHLIGHTS**

40 • Three APEC strains were characterized and selected to develop in vivo models of colibacillosis

41 • A bivalent autogenous vaccine was produced and a passive immunization trial was carried out

42 • Protection of chicks was demonstrated when challenged with the 19-383-M1 APEC strain  
43 (homologous challenge)

44 • Further work is needed in particular to evaluate the protection against heterologous challenge

45

46 **KEYWORDS**

47 *Escherichia coli*, broiler, day-old-chicks, pathogen model, challenge, mortality, autogenous vaccine,  
48 passive immunization

49

50 **Introduction**

51  
52 Avian pathogenic *Escherichia coli* (APEC) cause extra-intestinal infections called colibacillosis, which –  
53 even more today – is the dominant bacterial disease on *Gallus gallus* farms (broilers and laying hens,  
54 in particular). Colibacillosis causes high mortality, high morbidity and high rates of carcass  
55 condemnations at the slaughterhouse; the resulting decrease in production leads to significant  
56 economic losses for the farmer. It also causes salpingitis and septicaemia in breeders. Moreover, APEC  
57 may be a potential foodborne zoonotic pathogen and a source or reservoir of extra-intestinal infections  
58 in humans (Moulin-Schouleur *et al.*, 2007; Mellata, 2013; Liu *et al.*, 2018). To control the disease,  
59 antibiotics such as beta-lactams, colistin and fluoroquinolones are used, most often by oral route and  
60 administered in the drinking water. These treatments constitute a proven risk of selection and  
61 dissemination of antimicrobial resistance genes and resistant bacterial strains, also leading to public  
62 health concern.

63 APEC harbour numerous virulence factors that cause colibacillosis. Two recent publications  
64 (Christensen *et al.*, 2021; Kathayat *et al.*, 2021) inventoried these virulence factors, which include  
65 adhesins, invasins, protectins, iron acquisition systems, toxins, a quorum-sensing system,  
66 transcriptional regulators, genes associated with metabolism; this list is not exhaustive. Moreover,  
67 APEC produce extracellular polymeric substances with more than 500 different proteins that may  
68 interact with the host, combined with other bacteria, *E. coli* or others (Eboigbodin & Biggs, 2008).  
69 Another, more recent paper (Delannoy *et al.*, 2021) evaluated the genetic diversity of *E. coli* strains  
70 isolated from 80 broiler flocks, monitored from before chick placement to colibacillosis outbreaks. The  
71 *E. coli* isolates were characterized using high-throughput qPCR to screen genetic markers related to 23  
72 serogroups, five phylogroups and 66 virulence factors and determine genetic profiles. In addition to  
73 other findings, the study highlighted the huge diversity among avian *E. coli* with, for example, some  
74 flocks for which day-old chicks (DOCs) harboured the genetic profile of colibacillosis cases identified in  
75 other flocks, but nevertheless remained healthy.

76           Beyond the concern related to colibacillosis, the strong regulatory, scientific and societal  
77 pressure to reduce the use of antibiotics in poultry farming has led to search for other strategies to  
78 control this disease, including the development of an efficient vaccine. Despite plenty of vaccine  
79 candidates demonstrating efficacy in chickens in experimental studies, only one vaccine is currently  
80 commercially available in most regions worldwide (Galal *et al.*, 2018; Chrétien *et al.*, 2021). It is an  
81 attenuated O78 *E. coli* strain and provides effective protection against a challenge with the O78 wild  
82 strain (Koutsianos *et al.*, 2020). However, according to the summary of the characteristics of this  
83 vaccine, the onset of immunity in chickens is established 2 weeks after vaccination with a reduction in  
84 colibacillosis lesions. Except for a few publications and under specific conditions (Mombarg *et al.*, 2014,  
85 where the overall mortality was very high), the efficacy of the vaccine was not established to reduce  
86 mortality (as shown in the summary of the product characteristics at  
87 <http://ircp.anmv.anses.fr/results.aspx>), although mortality appears to be one of the most common  
88 clinical manifestations of colibacillosis (Kemmett *et al.*, 2014). In addition, according to some studies  
89 (Ghunaim *et al.*, 2014; Guabiraba & Schouler, 2015), this type of vaccine is less efficient against *E. coli*  
90 heterologous strains (e.g. belonging to other serogroups or phylogroups). Therefore, this vaccine  
91 sometimes suffers from limited efficacy, given the diversity of APEC strains and the difficulty of  
92 obtaining a satisfactory level of protection as early as hatch time.

93           Autogenous vaccines may be one way to address and respond to this diversity of strains. They  
94 are produced from APEC strains isolated from the affected flock in which the autogenous vaccine is to  
95 be administered. This type of vaccine can be used either directly on target animals (Landman & van  
96 Eck, 2017; Kromann *et al.*, 2021) or via a passive immunization strategy (i.e. administration of the  
97 vaccine to the broiler breeders to protect the DOCs by means of antibodies transmitted by their  
98 mother). Although it has yet to be demonstrated that autogenous vaccines can protect against  
99 heterologous APEC strains, it is easier to adapt their composition compared to that of a commercial  
100 vaccine, due to the heaviness of the drug marketing authorization process. Because of this, autogenous  
101 vaccines can more easily solve the diversity of APEC strains. To our knowledge, no satisfactory vaccine

102 is available against colibacillosis in broilers and, to date, only two publications have reported possible  
103 protection of DOCs using passive immunization (Rosenberger *et al.*, 1985; Heller *et al.*, 1990).

104 Here, we describe two experiments. In the first one, three APEC strains that have been  
105 characterized (Delannoy, *et al.*, 2021) in terms of virulence factor content, serogroup and phylogroup  
106 were used to develop *in vivo* models of colibacillosis for DOCs on two chicken breeds. The first one is  
107 the ANSES' own Leghorn breed and the second one is the Ross 308 breed (Aviagen company<sup>®</sup>), and is  
108 the most common broiler breed in Europe. The use of two chicken breeds made it possible to check  
109 the sensitivity of our specific-pathogen-free (SPF) Leghorn breed to the *E. coli* challenge compared with  
110 that of Ross 308. This comparison allowed us to validate the use of our Leghorn SPF hens for the second  
111 experiment rather than the Ross 308 SPF hens, which were not available. In the second experiment, a  
112 passive immunization challenge study was then performed on broilers using a bivalent autogenous  
113 vaccine administered to breeder hens.

## 114 **Materials and methods**

### 115 ***Selection and characterization of APEC strains and preparation of mutants and inocula***

116 **Selection of three representative strains.** The experiments described in this manuscript are part of a  
117 French nationwide project that has been partly recently published (Delannoy *et al.*, 2021) and for  
118 which the original data involved 1050 environmental or clinical *E. coli* isolates on which 68 variables  
119 were measured (i.e. phylogroup markers, serogroups and 66 virulence markers). Our first aim was to  
120 select three representative strains that cause colibacillosis disease for the experimental trials;  
121 therefore, statistical analyses were applied to a set of 269 *E. coli* strains from colibacillosis-diseased  
122 chickens only. First, non-informative variables (i.e. same value for all the strains) were discarded.  
123 Second, categorical variables were quantified and summarized using a multiple correspondence  
124 analysis (MCA) (Greenacre, 1984). The most informative MCA components were used as variables  
125 instead of the original ones. Third, a hierarchical clustering (Sokal & Sneath, 1963) approach was  
126 applied to the selected MCA components to choose the optimal number of clusters. Fourth, clustering

127 was optimized using the k-means method (Lloyd, 1982; MacQueen, 1967) applied to the optimal  
128 number of clusters. Finally, the most representative strains (i.e. closest to the mode of the cluster) of  
129 each k-means cluster were identified. The R functions 'MCA' and 'hclust' of the 'FactoMiner' package  
130 (Lê *et al.*, 2008), and the 'kmeans' function were used. At the end of the process, three clusters were  
131 obtained and three APEC strains representative of each cluster were selected: *E. coli* 19-381 (cluster  
132 1), 19-383 (cluster 2) and 19-385 (cluster 3) as shown in the figure 1.

133 **Preparation of mutants and inocula.** To facilitate the recovery of the strains from internal organs  
134 during *in vivo* assays, spontaneous rifampicin-resistant mutants of *E. coli* 19-381, 19-383 and 19-385  
135 were obtained by culturing the strains on Mueller-Hinton (MH) medium containing rifampicin (250  
136 mg/L). No mutant was obtained for strain 19-381. The mutants were compared with parental strains,  
137 in terms of their phylogenetic group (Clermont *et al.*, 2000) and their antimicrobial susceptibility  
138 determined by a broth micro-dilution method on EUVSEC plates (Sensititre, ThermoFisher Scientific,  
139 Dardilly, France). Then the *E. coli* strain (19-381) and the obtained mutants (19-383-M1 and 19-385-  
140 M1) were cultured overnight in MH broth at 37°C under agitation. The cultures were centrifuged and  
141 re-suspended in peptone buffer to obtain a titre of approximately  $3 \times 10^8$  colony forming units (CFU)/mL  
142 for both *in vivo* trials. The objective was to be in conformity with Schouler *et al.* (2012) where the dose  
143 inoculated per chick was about  $5 \times 10^7$  CFU. The titres were determined by plating decimal dilutions on  
144 MH agar plates.

145 **Whole genome sequencing and characterization of the three strains.** Whole genome sequencing  
146 (WGS) was performed on a Novaseq 6000 system with the Nextera kit. The raw reads were processed  
147 using the shovill method (<https://github.com/tseemann/shovill>, not published yet) with the "--trim"  
148 option. This method cleaned raw reads using trimmomatic (Bolger *et al.*, 2014) and assembled the  
149 reads using Spades to generate contigs (Prjibelski *et al.*, 2020). The de novo contigs were then screened  
150 against Megablast (Chen *et al.*, 2015) on a local nucleotide database. All contigs belonged to *E. coli*  
151 strains. The contigs shorter than 200 nucleotides or with a k-mer coverage lower than 2 were filtered  
152 out. The sequences were analysed using the tools from the Center for Genomic Epidemiology (CGE,



153 <https://www.genomicepidemiology.org> to determine the main characteristics of the strains  
154 (serotype, sequence type (ST), resistance genes and *E. coli* virulence genes) and to the ClermonTyper  
155 (<http://clermontyping.iame-research.center/>) to determine phylogroups. The susceptibility of the  
156 three strains was studied by disk diffusion assay according to the AFNOR NF U47-107 (2012).

### 157 ***Pathogenicity of three E. coli strains (19-381, 19-383-M1 and 19-385-M1) on day-old chicks***

158 The virulence of the selected APEC strains was evaluated in a lethality assay by subcutaneous  
159 inoculation into DOCs and for two chicken breeds (Leghorn and Ross 308). For this experiment, we  
160 used chicks hatched from 45-week-old and 40-week-old for SPF Leghorn and Ross 308 hens  
161 respectively. The experimental design is shown in the table 1. Four groups were defined for each  
162 chicken breed. Leghorn groups were: L-NI (non-infected), L-381 (infected with 19-381), L-383M  
163 (infected with 19-383-M1), L-385M (infected with 19-385-M1). Ross 308 groups were: R-NI (non-  
164 infected), R-381 (infected with 19-381), R-383M (infected with 19-383-M1), R-385M (infected with 19-  
165 385-M1). The experiment was performed in accordance with French animal welfare regulations and  
166 the protocol was approved by the ANSES/ENVA/UPEC Ethics Committee and the French Ministry for  
167 Higher Education, Research and Innovation (APAFIS #21978-2019091215094222V1). The experiment  
168 was conducted at the ANSES Ploufragan animal facilities. Four rooms and two pens per room were  
169 used. The chicks were tagged with unique numbers and housed in negative pressure, air-filtered, level-  
170 2 containment rooms in floor pens with wood shavings as bedding material. The DOCs were distributed  
171 in the rooms in such a way to obtain similar average weights across the different experimental groups.  
172 They were then inoculated subcutaneously (0.1 mL per chick, at the neck level between the two wings)  
173 according to the experimental design outlined in Table 1. Daily mortality and clinical status (normal,  
174 slightly depressed, prostrate) were monitored until the end of the experiment, eight days after  
175 inoculation. Body weight was assessed before inoculation and at the end of the experiment. In case of  
176 mortality, or for 10 live birds at the end of the experiment, colibacillosis lesions were determined and  
177 liver and spleen samples were collected. All liver and spleen samples were grown on MacConkey (MC)  
178 media. The samples from birds inoculated with *E. coli* 19-383-M1 or *E. coli* 19-385-M1 were grown on

179 MC media supplemented with rifampicin (250 mg/L), and those from birds inoculated with *E. coli* 19-  
180 381 or *E. coli* 19-383-M1 were grown on MC supplemented with ciprofloxacin (0.25 mg/L). Hence, the  
181 choice of the antibiotic used for selection was based on the resistance of the different strains. Samples  
182 from the non-inoculated birds were grown on all three media. For each positive sample, one  
183 randomly chosen colony was identified with an *E. coli*-specific PCR (Furet *et al.*, 2009), and its  
184 phylogenetic group was determined (Clermont *et al.*, 2000; Peebles *et al.*, 2005)

### 185 ***APEC autogenous vaccine***

186 The autogenous vaccine used was an inactivated and adjuvanted vaccine produced by an authorized  
187 laboratory (Laboceca, Ploufragan, Laboratory 1879, authorization AV 0787/07 delivered by the French  
188 National Veterinary Medicines Agency for the manufacture of veterinary autogenous vaccines, in  
189 accordance with French regulations). The vaccine included the APEC 19-381 and 19-383-M1 strains,  
190 because the 19-385-M1 strain induced no mortality nor clinical signs (see Results). The antigenic  
191 fraction was composed of the corresponding whole bacterial cells, whose culture was carried out in  
192 broth then in agar medium (PPLO agar base, Difco). The bacterial cells were harvested by adding 0.9%  
193 NaCl physiological serum for injection (Fresenius Kabi), supplemented with 0.5% of a 37%  
194 formaldehyde solution (Sigma Aldrich) to inactivate the bacteria. The concentration of bacterial cells  
195 in the aqueous phase collected was between  $10^8$  and  $10^9$  CFU/mL. This aqueous phase was then  
196 emulsified with an oily adjuvant ISA35 (SEPPIC) to produce an oil/water vaccine, the adjuvant  
197 representing 25% (vol/vol) of the final mixture. The inactivation of the bacteria and the sterility of the  
198 autovaccine were checked using tests on broths and subcultures on agar medium with a final reading  
199 at 14 days, in accordance with the guidelines of the European Pharmacopoeia. Each breeder hen was  
200 inoculated in the pectoral muscle with 0.3 mL of the vaccine, as described below.

### 201 ***Passive immunization experiment***

202 This second experiment was also performed in accordance with the same welfare and ethics  
203 regulations (authorization number APAFIS #24443-2020030217596117V3). The experiment was  
204 conducted at the ANSES Ploufragan animal facilities. Forty SPF Leghorn layers from ANSES Ploufragan,  
205 housed in furnished cages, were randomly distributed in two groups and two separate rooms: 20 layer  
206 hens were vaccinated twice at 20 and 22 weeks of age and the other 20 layer hens received a saline  
207 solution at the same ages (control group). Each room housed four non-vaccinated SPF Leghorn roosters  
208 as well, which were previously distributed at random. Fertile eggs were collected for two weeks after  
209 the second vaccination: these eggs were thus collected from 22 to 24 week-old hens. The hens were  
210 observed for clinical evaluation from the first injection until the end of egg collection. Fertile eggs from  
211 both hen groups were incubated in the same incubator, but care was taken to avoid mixing them up.  
212 DOCs were then obtained from vaccinated and non-vaccinated hens. Six groups of 20 chicks were then  
213 randomly formed so as to obtain similar average weights (and standard deviation) in the different  
214 groups (Table 2). All chicks were tagged with unique numbers. The chicks of a given group were housed  
215 in negative-pressure level-2 isolators with a volume of 1.36 m<sup>3</sup> each (these isolators are made to order  
216 for our institute). The same parameters as for the pathogenicity experiment were recorded: daily  
217 mortality and clinical status until the end of the experiment, body weight before inoculation and at the  
218 end of the experiment. In case of mortality or for all live birds at the end of the experiment,  
219 colibacillosis lesions were determined and liver and spleen samples were collected.

220 The experimental design is presented in the table 2. Six groups of chicks were defined: non-  
221 vaccinated and non-challenged (NVNC), vaccinated and non-challenged (VNC), two groups of non-  
222 vaccinated and challenged (NVC 381 and NVC 383M, respectively challenged with 19-381 and 19-383-  
223 M1) and two groups of vaccinated and challenged (VC 381 and VC 383M, respectively challenged with  
224 19-381 and 19-383-M1). On their first day of life, the chicks from the NVC 381, NVC383 M, VC 381, and  
225 VC 383M groups were challenged as described for the first experiment. Mortality, clinical status and  
226 lesions of dead birds or birds sacrificed on day 9 were recorded as described above. Organs were  
227 cultured as for the first trial, but only one isolate was characterized from each organ.

## 228 **Statistics**

229 For both experiments, the qualitative variables (i.e. mortality, clinical status) were analysed using a  
230 Chi-square test, or Fisher's exact test for small samples ( $n \leq 5$ ). The quantitative data were analysed  
231 using either an analysis of variance or a Wilcoxon test depending on the number of observations and  
232 the parametric hypothesis checking. The level of significance was set to  $p \leq 0.05$ .

## 233 **Sequences**

234 The sequences were deposited in GenBank and are available from the NCBI, BioProject  
235 PRJNA795346 (Accessions SRR17934378, SRR17934377 and SRR17934376).

## 236 **Results**

### 237 ***Characterization of the three representative E. coli strains and mutants obtained***

238 The genetic characteristics of the colibacillosis isolates obtained were used to select three strains  
239 representative of the three clusters on the basis of the characteristics (i.e. phylogroup, serogroup and  
240 66 virulence markers) of the 269 colibacillosis strains. A hierarchical clustering procedure was  
241 performed using 45 variables (variables with no variability were removed) and 268 strains (one atypical  
242 strain was discarded). Then, a k-means method was applied with  $k = 3$  classes. The three k-means  
243 clusters, containing respectively 57, 82 and 129 strains, were the same as with those identified in the  
244 hierarchical clustering (Figure 1).

245 Cluster 1 contained mostly isolates belonging to the B2 phylogroup, and to the O2:K1  
246 serogroup, and possessing several plasmid virulence associated genes (e.g. *iut*, *ompT*, *tsh*), and also  
247 the *ibeA* gene, absent in most isolates of Clusters 2 and 3. Cluster 2 contained isolates belonging  
248 mostly to phylogroup F, and possessing the *pic*, *fimA1* and *ireA* genes, which are absent in most  
249 isolates of Clusters 1 and 3. Cluster 3 included mostly isolates belonging to phylogroup B1 and  
250 possessing, unlike most isolates of Clusters 1 and 2, the genes ETT2.2, *fepC*, *hcp* and *hra*. Finally, for

251 each class, the most representative strains (i.e. *E. coli* 19-381, 19-383 and 19-385) were selected. *E.*  
252 *coli* 19-381 shared all the characteristics presented in Table 3 for strains of Cluster 1, except the *iha*  
253 and *csgA3* genes. *E. coli* 19-383 shared the characteristics of Cluster 2, except the *iutA* and *cma*  
254 genes. Based on its genomic sequence, *E. coli* 19-383 was shown to belong to phylogroup G, a  
255 recently described phylogroup intermediate between the F and B2 phylogroups. Thirty out of 39 of  
256 the characteristics of Cluster 3 were present in *E. coli* 19-385.

257         The three selected strains had been obtained from cases of early colibacillosis (i.e. broiler  
258 flocks of up to 10 days of age with a daily mortality rate higher than 0.3% and suspect clinical signs or  
259 typical colibacillosis lesions). Susceptibility tests showed that *E. coli* 19-381 was resistant to  
260 sulfamethoxazole, trimethoprim, tetracycline, ciprofloxacin and ampicillin; *E. coli* 19-383 was resistant  
261 to sulfamethoxazole, trimethoprim, tetracycline, ciprofloxacin, ampicillin and chloramphenicol and *E.*  
262 *coli* 19-385 was resistant to sulfamethoxazole and tetracycline.

263 We were able to obtain rifampicin-resistant mutants for *E. coli* 19-383 and *E. coli* 19-385, but not for  
264 *E. coli* 19-381. The two mutants belonged to the same phylogenetic group as their parental strains and  
265 susceptibility testing showed that, in addition to rifampicin resistance, the mutants *E. coli* 19-383-M1  
266 and *E. coli* 19-385-M1 were resistant to the same antibiotics as their parental strains. Thus the *in vivo*  
267 experiments were performed with *E. coli* 19-381 and the mutants *E. coli* 19-383-M1 and *E. coli* 19-385-  
268 M1 .

269         Results of the WGS of these three strains are presented in Table 4. The *E. coli* 19-381, 19-383-  
270 M1 and 19-385-M1 strains belonged respectively to serotypes O50/O2:H5:K1, O24:H4 and O86:H51,  
271 and to ST140, ST117 and ST155. Phylogroups determined by PCR were confirmed by WGS. Based on  
272 the various virulence-associated genes screened for using qPCR and the CGE web tool, *E. coli* 19-381  
273 and 19-383-M1 had a high number of virulence-associated genes (39 each), whereas 29 virulence-  
274 associated genes were detected in *E. coli* 19-385-M1. The first two strains had the ciprofloxacin  
275 resistance mutation in the *gyrA* gene (S83L) and harboured genes encoding resistance to beta-lactams,

276 tetracyclines, sulfonamides, trimethoprim and aminoglycosides. *E. coli* 19-383-M1 also had resistance  
277 genes to macrolides and chloramphenicol. *E. coli* 19-385-M1 had only resistance genes to beta-lactams  
278 and tetracyclines.

### 279 ***Pathogenicity experiment***

280 Numbers of bacteria inoculated per chick were  $3.2 \times 10^7$ ,  $3.4 \times 10^7$  and  $2.6 \times 10^7$  CFU for *E. coli* 19-381,  
281 19-383-M1 and 19-385-M1, respectively.

282 Observed mortality and clinical status are given in Table 5. The virulence profile for chicks of  
283 the three APEC strains was quite different. Mortality in Ross 308 was 0% (R-NI and R-385M groups),  
284 84% (R-383M group) and 100% (R-381 group), all chicks dying as early as the day following inoculation  
285 for R-381. The surviving chicks (R-383M) presented a significantly more severe clinical state compared  
286 with the control group until Day 4 (D4), the difference in score distribution being non-significant  
287 thereafter. Regarding the Leghorn chicks, mortality was 0% (L-NI and L-385M), 52% (L-383M) and 100%  
288 (L-381), all chicks dying before D4 for L-381. The surviving chicks (L-383M) presented a significantly  
289 more severe clinical state compared with the control group until D4, the difference being non-  
290 significant thereafter. Thus, the two chicken breeds were susceptible to colibacillosis, although the  
291 mortality rate was significantly higher for Ross 308 than for Leghorns for APEC 19-383-M1.

292 For the Ross 308 chicks, the average body weight at the end of the study was 173.0 g (25 chicks;  
293 standard deviation (SD), 25.5 g) for the R-NI group, 123.5 g (4 chicks; SD, 17.2 g) for the R-383M group  
294 and 165.0 g (25 chicks, SD, 23.5 g) for the R-385M group. The average weight was significantly higher  
295 in the R-NI and the R-385M groups than in the R-383M group ( $p = 0.001$ , ANOVA). The average weights  
296 of the R-NI and R-385M groups were not significantly different. Regarding the Leghorn chicks, the  
297 average body weight at the end of the study was 92.2 g (25 chicks; SD, 7.2 g) for the L-NI group, 79.4 g  
298 (12 chicks; SD, 8.3 g) for the L-383M group and 89.2 g (24 chicks; SD, 8.5 g) for the L-385M group,  
299 respectively. This average weight was significantly higher in the L-NI ( $p < 0.001$ ) and the L-385M

300 (p=0.002) groups than in the L-383M group. The average weights of the L-NI and L-385M groups were  
301 not significantly different.

302           Regarding post-mortem findings, no lesions were observed in the control group. When death  
303 was sudden, there was generalized congestion. Conversely, when the chicks survived a few days,  
304 pericarditis and perihepatitis were observed. Within each group, the numbers of positive liver and  
305 spleen samples on the different media tested (MC, MC-Rif and MC-Cip) were not significantly different  
306 (p>0.05). All cultures from the control non-inoculated group were negative. Overall, for the group  
307 inoculated with *E. coli* 19-381, all analysed chicks were positive. For the group inoculated with *E. coli*  
308 19-383-M1, 19 out of 25 Leghorn and 24 out of 25 Ross 308 chicks were positive (p>0.05). For the  
309 group inoculated with *E. coli* 19-385-M1, 4 out of 10 Leghorn and 3 out of 10 Ross 308 chicks were  
310 positive (p>0.05). The numbers of positive chicks in the inoculated groups were significantly different  
311 from each other, with the highest proportion in the 19-381 inoculated group (32 positive chicks out of  
312 32 analyzed), the lowest proportion in the 19-385-M1 group (7 positive chicks out of 20 analyzed), and  
313 the 19-383-M1 group showing an intermediate proportion (43 positive chicks out of 50 analyzed). All  
314 isolates (153 from MC, 142 from MC-CIP and 85 from MC-Rif) belonged to the expected phylogroups.

### 315 ***Passive immunization experiment***

316 No clinical signs were observed in the vaccinated or the control hens. Moreover, egg production and  
317 fertility of both groups were similar. For this experiment, the dose of *E. coli* (in CFU in 0.1 ml volume)  
318 that was administered per chick was  $1.2 \times 10^7$  and  $3.2 \times 10^7$  for strains 19-381 and 19-383-M1,  
319 respectively.

320           Results are presented in Table 6. No mortality nor clinical signs occurred in the control groups  
321 (negative control and vaccine control). No significant difference was observed, either in mortality (90%  
322 versus 95%) or in the clinical status over time, between the non-vaccinated and vaccinated chicks that  
323 were challenged with the APEC 19-381 strain. Conversely, for chicks that were challenged with the  
324 APEC 19-383-M1 strain, the mortality rate was significantly lower in the vaccinated group (40%) than

325 in the non-vaccinated group (80%), as shown in Figure 2 ( $p < 0.05$ ). However, no significant differences  
326 were observed between groups for their clinical status over time.

327 For the comparisons that were carried out (vaccinated vs non-vaccinated groups that were  
328 challenged with either *E. coli* strain 19-381 or 19-383-M1), no significant differences were noted  
329 between the different groups regarding body weight at day 9. Regarding post-mortem findings, the  
330 results obtained during the first experiment were confirmed: generalized congestion in case of rapid  
331 death or pericarditis and/or perihepatitis for chicks that survived several days.

332 Similar to the first trial, results obtained on the three media were not significantly different  
333 ( $p > 0.05$ ). Overall, most samples from challenged chicks, vaccinated or not, were found positive by  
334 culture. All birds collected up to and on day 6 were positive. Thereafter, only two birds of the NVC381  
335 and one from the VC383 group were negative. All tested isolates (46 from the MC media, 40 from the  
336 MC-CIP media and 23 from the MC-Rif media) belonged to the expected phylogroup.

## 337 Discussion

338 The genes and mutations detected in the genomes of the three strains were consistent with the  
339 susceptibility phenotypes, i.e. the mutation S83L in the *gyrA* gene of *E. coli* 19-381 and 19-383  
340 leading to quinolone resistance, and the presence of the following resistance genes: *bla*<sub>TEM-1B</sub> for  
341 resistance to ampicillin (19-381), *tet(A)* or *tet(B)* for resistance to tetracycline (the three strains), *sul1*  
342 or *sul2* for resistance to sulfamethoxazole (the three strains), *dfrA1* for resistance to trimethoprim  
343 (19-381 and 19-383) and *catA1* for resistance to chloramphenicol (19-383). *E. coli* 19-381 and 19-383  
344 also had *strA*, *strB* or *aadA1*, which encode resistance to streptomycin, but this antibiotic was not  
345 tested.

346 *E. coli* 19-381 is a O50/O2:K1 :H5, B2, ST140 isolate. Indeed *E. coli* strains belonging to this ST  
347 have been reported among the most prevalent isolated from avian colibacillosis and may be involved  
348 in human diseases: Mehat *et al.* (2021) reported that the O1 and O2 serotypes, which represent with



349 O78 80% of APEC isolates, belong to a lineage including ST-95, ST140 and ST428/ST429 strains. Zhu  
350 Ge *et al.* (2014) studied the APEC isolate IMT5155 (O2:K1:H5; ST140), isolated from a diseased  
351 chicken in Germany in 2000, and showed that it shared close relationship with ST95 APEC O1:K1 and  
352 human ExPEC O18:K1 strains. *E. coli* 19-383-M1 belongs to serotype O24:H4, phylogroup G. Indeed,  
353 phylogroup G is composed of one main ST complex, STc117, a poultry-associated lineage with  
354 extensive resistance to antibiotics (Clermont *et al.*, 2019). *E. coli* 19-383M1 carries most of the  
355 virulence genes frequently present in strains of STc117 (Clermont, *et al.*, 2019). ST117 APEC were  
356 previously found to be implicated in large outbreaks of colibacillosis in both parents and broilers in  
357 Nordic countries (Ronco *et al.*, 2017). Thus, the two strains selected to prepare the autogenous  
358 vaccine are clearly important poultry pathogens. *E. coli* 19-381 and 19-383 were highly virulent for  
359 DOCs, because they induced a high percentage of mortality within a few days. Both strains contain a  
360 high number of virulence-associated genes. In particular, they have five (19-381) or four (19-383) of  
361 the predictors of pathogenicity (*iss*, *iutA*, *hlyF*, *iroN* and *ompT*) proposed by Johnson (Johnson *et al.*,  
362 2008) and, according to this scheme, they would be classified as virulent. Regarding the *E. coli* 19-385  
363 strain, in our experimental conditions, it was not virulent for DOCs. Interestingly, this strain contains  
364 the plasmid virulence-associated genes *hlyF*, *iroN*, *iss* and *ompT*, and would have been classified as  
365 virulent according to the scheme of Johnson (Johnson *et al.*, 2008), whereas according to the  
366 diagnostic strategy proposed by Schouler *et al.* (2012) *E. coli* 19-381 would be classified as virulent  
367 but not *E. coli* 19-383 and *E. coli* 19-385.

368           Regardless of the chicken strain used in the first experiment, challenge with APEC 19-381  
369 resulted in 100% mortality four days post-inoculation at the latest. Mortality during the second  
370 experiment was at least 90%. This APEC strain probably has a lower lethal dose than the 19-383-M1  
371 strain. For the *E. coli* strains that were pathogenic, mortality rate or pattern was different for the Ross  
372 308 and for the Leghorn breeds. Thus, significantly higher mortality was observed in the R-383M (Ross  
373 308 chicks infected with 19-383-M1 strain) group (84%) than in the L-383M (Leghorn chicks infected  
374 with 19-383-M1 strain) group (52%). Regarding the APEC 19-381 strain, although the mortality rate

375 was 100% for both chicken breeds, all R-381 chicks (Ross 308, infected with 19-381 strain) died before  
376 D1, whereas mortality was slightly delayed for the L-381 chicks (Leghorn, infected with 19-381 strain),  
377 all of them dying before D4. This difference in susceptibility of the two chicken breeds is in line with  
378 other studies (Yunis *et al.*, 2000; Ask *et al.*, 2006) and may be due to their different growth rates.  
379 Likewise, several studies have demonstrated an inverse relationship between growth rate and  
380 resistance to colibacillosis (Yunis, *et al.*, 2000; Yunis *et al.*, 2002); the average daily weight gain was 13  
381 g/day and 5 g/day in the Ross 308 R-NI (non-infected) and Leghorn L-NI (non-infected) groups,  
382 respectively.

383         The mortality induced by the APEC 19-383-M1 strain in Leghorn chicks was different between  
384 the two experiments (52% mortality in experiment 1 vs 80% in experiment 2). This difference may be  
385 related to breeder age. The layers were 45 weeks old in experiment 1 versus 22 to 24 weeks old in  
386 experiment 2. Mortality during the first week of life is higher in chicks from young hens, thus indicating  
387 a greater fragility of these chicks (Pedroso *et al.*, 2005; Peebles, *et al.*, 2005). In the present study, we  
388 successfully demonstrated the partial protection of chicks through the vaccination of breeder hens.  
389 Our results show that APEC 19-383-M1 caused 40% mortality in chicks from hens that were vaccinated,  
390 compared with 80% for chicks from hens that were non-vaccinated. This protection against  
391 homologous APEC strains is in line with the two passive immunization studies that have been published  
392 to date for chickens (Rosenberger, *et al.*, 1985; Heller, *et al.*, 1990). According to these authors, the  
393 passive immunization process is linked to the level of maternally derived antibodies following hen  
394 vaccination. In addition, there is a correlation between the hen's antibody titre and percentage of  
395 survival of her progeny.

396         Due to the diversity of APEC strains and the need for an acceptable level of protection as early as  
397 hatch time, no satisfactory commercial vaccine is currently available. Under these circumstances,  
398 recent publications have highlighted new knowledge on APEC colonization and the usefulness of  
399 autogenous vaccines. Today, most scientists agree that *E. coli* colonizing DOCs may originate from their

400 mother hens (Poulsen *et al.*, 2017). These studies estimate horizontal spreading of *E. coli* in the hatcher  
401 to be 95% in comparison to the 5% of genuine vertical transfer. On the other hand, a recent paper  
402 (Lozica *et al.*, 2021) investigated the effect of autogenous *E. coli* vaccines on the prevalence of 84  
403 virulence-associated genes in *E. coli* isolated from four and five consecutive flocks at two broiler  
404 breeder farms. Results indicate that continuous application of autogenous vaccines led to lower  
405 genetic diversity of *E. coli* housekeeping genes, even if no such effect was observed for the diversity of  
406 virulence genes. The successful use of autogenous vaccines, including through passive immunization,  
407 will require a rational and judicious choice of the included APEC strains: characterization of the strains,  
408 determination of their pathogenicity using modern methods (machine learning, etc.), to establish a  
409 link between clinical outbreaks and other factors, including management (Christensen, *et al.*, 2021).

## 410 **Conclusion**

411 In this study, for our experimental trials, we selected three representative strains (19-381, 19-383-M1  
412 and 19-385-M1) among several hundred APEC strains that cause colibacillosis disease. We first  
413 performed pathogenicity experiments to develop colibacillosis in *in vivo* models. Two APEC strains (19-  
414 381 and 19-383-M1) were found to be highly virulent for DOCs, whereas the 19-385-M1 strain induced  
415 no mortality or morbidity. We then developed a bivalent autogenous vaccine (19-381 and 19-383-M1)  
416 and carried out a passive immunization trial. We demonstrated partial protection of chicks when  
417 challenged with the 19-383-M1 strain. Further work is needed to assess the effect of the APEC  
418 challenge dose inoculated, hen age, the persistence and mechanisms of protection by passive  
419 immunization, the number of APEC strains to use in the autogenous vaccine, the judicious choice of  
420 adjuvants and the heterologous protection of the vaccine made from strain 19-383-M1.

## 421 **Funding**

422 This work was supported by the French Ministry of Agriculture (General Education and Research  
423 Department, grant ITAVI-DGER 16/110), and the French broiler association (Comité interprofessionnel  
424 du poulet de chair).

425 **Declaration of Competing Interest**

426 The authors report no declarations of interest.

427 **Acknowledgments**

428 The authors are grateful to the veterinarians and farmers who participated in the study, the Finalab,  
429 Labocea, and Resalab laboratories for isolating the strains and the staff of Anses facilities for taking  
430 care the study animals.

431 **References**

- 432 Ask, B., van der Waaij, E.H., Stegeman, J.A. & van Arendonk, J.A. (2006). Genetic variation  
433 among broiler genotypes in susceptibility to colibacillosis. *Poultry Science*, 85, 415-  
434 421.
- 435 Bolger, A.M., Lohse, M. & Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina  
436 sequence data. *Bioinformatics*, 30, 2114-2120.
- 437 Chen, Y., Ye, W., Zhang, Y. & Xu, Y. (2015). High speed BLASTN: an accelerated MegaBLAST  
438 search tool. *Nucleic Acids Research*, 43, 7762-7768.
- 439 Chrétien, L., Boutant, J., Lyazrhi, F. & Galliard, N. (2021). Retrospective assessment of  
440 *Escherichia coli* vaccination in broiler turkeys under field conditions in 37 farms from  
441 Brittany (France). *Avian diseases*, 65, 659-662.
- 442 Christensen, H., Bachmeier, J. & Bisgaard, M. (2021). New strategies to prevent and control  
443 avian pathogenic *Escherichia coli* (APEC). *Avian Pathology*, 1-12.
- 444 Clermont, O., Bonacorsi, S. & Bingen, E. (2000). Rapid and simple determination of the  
445 *Escherichia coli* phylogenetic group. *Applied and Environmental Microbiology*, 66,  
446 4555-4558.
- 447 Clermont, O., Ojas V. A. D., Vangchhia, B., Condamine, B., Dion, S., Bridier-Nahmias, A.,  
448 Denamur, E. & Gordon, D. (2019). Characterization and rapid identification of  
449 phylogroup G in *Escherichia coli*, a lineage with high virulence and antibiotic  
450 resistance potential. *Environmental Microbiology*, 21, 3107-3117.
- 451 Delannoy, S., Schouler, C., Souillard, R., Yousfi, L., Le Devendec, L., Lucas, C., Bougeard, S.,  
452 Keita, A., Fach, P., Galliot, P., Balaine, L., Puterflam, J. & Kempf, I. (2021). Diversity of  
453 *Escherichia coli* strains isolated from day-old broiler chicks, their environment and  
454 colibacillosis lesions in 80 flocks in France. *Veterinary Microbiology*, 252, 108923.
- 455 Eboigbodin, K.E. & Biggs, C.A. (2008). Characterization of the extracellular polymeric  
456 substances produced by *Escherichia coli* using infrared spectroscopic, proteomic, and  
457 aggregation studies. *Biomacromolecules*, 9, 686-695.
- 458 Furet, J.P., Firmesse, O., Gourmelon, M., Bridonneau, C., Tap, J., Mondot, S., Doré, J. &  
459 Corthier, G. (2009). Comparative assessment of human and farm animal faecal  
460 microbiota using real-time quantitative PCR. *FEMS Microbiology Ecology*, 68, 351-  
461 362.
- 462 Galal, H.M., Tawfek, A.M., Abdrabou, M.I., Hessain, A.M., Alhaaji, J.H., Kabli, S.A., Elbehiry,  
463 A., Alwarhi, W. & Moussa, I.M. (2018). Recent approaches for control of *E. coli* and  
464 respiratory complex in Middle East. *Saudi journal of biological sciences*, 25, 1302-  
465 1307.
- 466 Ghunaim, H., Abu-Madi, M.A. & Kariyawasam, S. (2014). Advances in vaccination against  
467 avian pathogenic *Escherichia coli* respiratory disease: potentials and limitations.  
468 *Veterinary Microbiology*, 172, 13-22.
- 469 Greenacre, M.J. (1984). Theory and applications of correspondence analysis. Academic Press,  
470 INC, Harcourt Brace Jovanovich Publishers, 364 pp.
- 471 Guabiraba, R. & Schouler, C. (2015). Avian colibacillosis: still many black holes. *FEMS*  
472 *Microbiology Letters*, 362.
- 473 Heller, E.D., Leitner, H., Drabkin, N. & Melamed, D. (1990). Passive immunisation of chicks  
474 against *Escherichia coli*. *Avian Pathology*, 19, 345-354.
- 475 Johnson, T.J., Wannemuehler, Y., Doetkott, C., Johnson, S.J., Rosenberger, S.C. & Nolan, L.K.  
476 (2008). Identification of minimal predictors of avian pathogenic *Escherichia coli*

477 virulence for use as a rapid diagnostic tool. *Journal of Clinical Microbiology*, 46, 3987-  
478 3996.

479 Kathayat, D., Lokesh, D., Ranjit, S. & Rajashekara, G. (2021). Avian pathogenic Escherichia coli  
480 (APEC): an overview of virulence and pathogenesis factors, zoonotic potential, and  
481 control strategies. *Pathogens*, 10, 467.

482 Kemmett, K., Williams, N.J., Chaloner, G., Humphrey, S., Wigley, P. & Humphrey, T. (2014).  
483 The contribution of systemic Escherichia coli infection to the early mortalities of  
484 commercial broiler chickens. *Avian Pathology*, 43, 37-42.

485 Koutsianos, D., Gantelet, H., Franzo, G., Lecoupeur, M., Thibault, E., Cecchinato, M., &  
486 Koutoulis, K.C. (2020). An assessment of the level of protection against colibacillosis  
487 conferred by several autogenous and/or commercial vaccination programs in  
488 conventional pullets upon experimental challenge. *Veterinary Science*, 7, 80.

489 Kromann, S., Olsen, R.H., Bojesen, A.M., Jensen, H.E. & Thøfner, I. (2021). Protective  
490 potential of an autogenous vaccine in an aerogenous model of Escherichia coli  
491 Infection in broiler breeders. *Vaccines*, 9, 12.

492 Landman, W.J.M. & van Eck, J.H.H. (2017). The efficacy of inactivated Escherichia coli  
493 autogenous vaccines against the E. coli peritonitis syndrome in layers. *Avian  
494 Pathology*, 46, 658-665.

495 Lê, S., Josse, J. & Husson, F. (2008). FactoMineR: an R package for multivariate analysis.  
496 *Journal of Statistical Software*, 25, 1-18.

497 Liu, C.M., Stegger, M., Aziz, M., Johnson, T.J., Waits, K., Nordstrom, L., Gauld, L., Weaver, B.,  
498 Rolland, D., Statham, S., Horwinski, J., Sariya, S., Davis, G.S., Sokurenko, E., Keim, P.,  
499 Johnson, J.R. & Price, L.B. (2018). Escherichia coli ST131-H22 as a foodborne  
500 uropathogen. *mBio*, 9, e00470-00418.

501 Lloyd, S.P. (1982). Least squares quantization in PCM. *IEEE Transactions on information  
502 theory*, vol. IT-28, 2, 129-137.

503 Lozica, L., Repar, J. & Gottstein, Z. (2021). Longitudinal study on the effect of autogenous  
504 vaccine application on the sequence type and virulence profiles of Escherichia coli in  
505 broiler breeder flocks. *Veterinary Microbiology*, 259, 109159.

506 MacQueen, J.B. (1967). Some methods for classification and analysis of multivariate  
507 observations. In L.M. Le Cam & J. Neyman (Eds.), University of California Press.  
508 *Proceedings of the fifth Berkeley symposium on mathematical statistics and  
509 probability*, 281–297.

510 Mehat, J.W., Van Vliet, A.H.M. & La Ragione, R.M. (2021). The Avian pathogenic Escherichia  
511 coli (APEC) pathotype is comprised of multiple distinct, independent genotypes.  
512 *Avian Pathology*, 50, 402-416.

513 Mellata, M. (2013). Human and avian extraintestinal pathogenic Escherichia coli: infections,  
514 zoonotic Risks, and antibiotic resistance Trends. *Foodborne Pathogens and Disease*,  
515 10, 916-932.

516 Mombarg, M., Bouzoubaa, K., Andrews, S., Vanimisetti, H.B., Rodenberg, J. & Karaca, K.  
517 (2014). Safety and efficacy of an aroA-deleted live vaccine against avian colibacillosis  
518 in a multicentre field trial in broilers in Morocco. *Avian Pathology*, 43, 276-281.

519 Moulin-Schouleur, M., Reperant, M., Laurent, S., Bree, A., Mignon-Grasteau, S., Germon, P.,  
520 Rasschaert, D. & Schouler, C. (2007). Extraintestinal pathogenic Escherichia coli  
521 strains of avian and human origin: link between phylogenetic relationships and  
522 common virulence patterns. *Journal of Clinical Microbiology*, 45, 3366-3376.

523

524 NF U47-107 (2012). Animal health analysis methods - Guidelines for conducting antibiograms  
525 using the diffusion method in an agar medium. ([https://www.boutique.afnor.org/en-](https://www.boutique.afnor.org/en-gb/standard/nf-u47107/animal-health-analysis-methods-guidelines-for-conducting-antibiograms-using/fa170310/40286#AreasStoreProductsSummaryView)  
526 [gb/standard/nf-u47107/animal-health-analysis-methods-guidelines-for-conducting-](https://www.boutique.afnor.org/en-gb/standard/nf-u47107/animal-health-analysis-methods-guidelines-for-conducting-antibiograms-using/fa170310/40286#AreasStoreProductsSummaryView)  
527 [antibiograms-using/fa170310/40286#AreasStoreProductsSummaryView](https://www.boutique.afnor.org/en-gb/standard/nf-u47107/animal-health-analysis-methods-guidelines-for-conducting-antibiograms-using/fa170310/40286#AreasStoreProductsSummaryView))  
528 Pedroso, A.A., Andrade, M.A., Cafe, M.B., Leandro, N.S., Menten, J.F. & Stringhini, J.H.  
529 (2005). Fertility and hatchability of eggs laid in the pullet-to-breeder transition period  
530 and in the initial production period. *Animal Reproduction Sciences*, 90, 355-364.  
531 Peebles, E.D., Keirs, R.W., Bennett, L.W., Cummings, T.S., Whitmarsh, S.K. & Gerard, P.D.  
532 (2005). Relationships among prehatch and posthatch physiological parameters in  
533 early nutrient restricted broilers hatched from eggs laid by young breeder hens.  
534 *Poultry Science*, 84, 454-461.  
535 Poulsen, L.L., Thofner, I., Bisgaard, M., Christensen, J.P., Olsen, R.H. & Christensen, H. (2017).  
536 Longitudinal study of transmission of Escherichia coli from broiler breeders to  
537 broilers. *Veterinary Microbiology*, 207, 13-18.  
538 Prjibelski, A., Antipov, D., Meleshko, D., Lapidus, A. & Korobeynikov, A. (2020). Using SPAdes  
539 de novo assembler. *Current Protocols in Bioinformatics*, 70, e102.  
540 Ronco, T., Stegger, M., Olsen, R.H., Sekse, C., Nordstoga, A.B., Pohjanvirta, T., Lilje, B., Lyhs,  
541 U., Andersen, P.S. & Pedersen, K. (2017). Spread of avian pathogenic Escherichia coli  
542 ST117 O78:H4 in Nordic broiler production. *BMC Genomics*, 18:13.  
543 Rosenberger, J.K., Fries, P.A. & Cloud, S.S. (1985). In vitro and in vivo characterization of  
544 avian Escherichia coli. III. Immunization. *Avian diseases*, 29, 1108-1117.  
545 Schouler, C., Schaeffer, B., Bree, A., Mora, A., Dahbi, G., Biet, F., Oswald, E., Mainil, J., Blanco,  
546 J. & Moulin-Schouleur, M. (2012). Diagnostic strategy for identifying avian pathogenic  
547 Escherichia coli based on four patterns of virulence genes. *Journal of Clinical*  
548 *Microbiology*, 50, 1673-1678.  
549 Sokal, R.P. & Sneath, P.H.A. (1963). Principles of numerical taxonomy. Publisher: San  
550 Francisco, W.H. Freeman, 359 pp.  
551 Yunis, R., Ben-David, A., Heller, E.D. & Cahaner, A. (2000). Immunocompetence and viability  
552 under commercial conditions of broiler groups differing in growth rate and in  
553 antibody response to Escherichia coli vaccine. *Poultry Science*, 79, 810-816.  
554 Yunis, R., Ben-David, A., Heller, E.D. & Cahaner, A. (2002). Antibody responses and morbidity  
555 following infection with infectious bronchitis virus and challenge with Escherichia  
556 coli, in lines divergently selected on antibody response. *Poultry Sciences*, 81, 149-159.  
557 Zhu Ge, X., Jiang, J., Pan, Z., Hu, L., Wang, S., Wang, H., Leung, F.C., Dai, J. & Fan, H. (2014). Comparative  
558 genomic analysis shows that avian pathogenic Escherichia coli Isolate IMT5155 (O2:K1:H5; ST Complex  
559 95, ST140) shares close relationship with ST95 APEC O1:K1 and human ExPEC O18:K1 Strains. *PLoS*  
560 *ONE*, 9, 1-16.

561

562

563

564

565

566 **Table 1.** Experimental design for the pathogenicity experiment

Room	Pen A	Pen B
1	25 SPF day-old chicks inoculated with sterile broth = <b>(L-NI)</b>	25 Ross 308 day-old chicks inoculated with sterile broth = <b>(R-NI)</b>
2	25 SPF day-old chicks inoculated with APEC 19-381 = <b>(L-381)</b>	25 Ross 308 day-old chicks inoculated with APEC 19-381 = <b>(R-381)</b>
3	25 SPF day-old chicks inoculated with APEC 19-383-M1 = <b>(L-383M)</b>	25 Ross 308 day-old chicks inoculated with APEC 19-383-M1 = <b>(R-383M)</b>
4	25 SPF day-old chicks inoculated with APEC 19-385-M1 = <b>(L-385M)</b>	25 Ross 308 day-old chicks inoculated with APEC 19-385-M1 = <b>(R-385M)</b>

567

568



569

570 **Table 2.** Experimental design for the passive immunization experiment.

<sup>a</sup> Group (group size)	Group type	Chicks from vaccinated hen	<i>E. coli</i> challenge strain
NVNC (20)	Negative control	No	No
NVC381 (20)	Non-vaccinated and challenged 19-381	No	19-381
NVC383M (20)	Non-vaccinated and challenged 19-383-M1	No	19-383-M1
VNC (20)	Vaccine control	Yes	No
VC381 (20)	Vaccinated and challenged 19-381	Yes	19-381
VC383M (20)	Vaccinated and challenged 19-383-M1	Yes	19-383-M1

571 <sup>a</sup>: The vaccine for hens is a bivalent autogenous vaccine prepared with *E. coli* 19-381 and 19-383-M1 strains

572

573

574

575

576

577

578

579

580 **Table 3.** Modes of the 39 significant variables for each cluster obtained using the k-means method performed on 268 *E. coli* strains and 45 descriptive  
 581 variables

Order of significance	Variable	Mode Cluster 1 (n=57)	Mode Cluster 2 (n=82)	Mode Cluster 3 (n=129)
1	Phylogroup	B2 (57)	F (74)	B1 (72)
2	Serogroup	O2 :K1(21)	O ? :H4 (52)	- (47)
3	<i>tkt1</i>	+ (57)	+ (82)	- (0)
4	<i>ibeA</i>	+ (55)	- (1)	- (0)
5	<i>frzorf4</i>	+ (56)	+ (82)	- (6)
6	<i>pic</i>	- (1)	+ (72)	- (0)
7	<i>csgA2</i>	+ (57)	- (7)	- (4)
8	<i>aec4</i>	+ (29)	+ (82)	- (0)
9	<i>csgA1</i>	- (0)	+ (75)	+ (118)
10	<i>yqic</i>	+ (57)	+ (82)	- (27)
11	<i>ETT2.2</i>	- (1)	- (1)	+ (91)
12	<i>fepC</i>	- (17)	- (8)	+ (114)
13	<i>fimA1</i>	- (7)	+ (82)	- (50)
14	<i>hcp</i>	- (1)	- (1)	+ (81)
15	<i>fepA3</i>	+ (31)	+ (82)	+ (129)
16	<i>ireA</i>	- (11)	+ (79)	- (47)
17	<i>hra</i>	- (7)	- (3)	+ (78)
18	<i>fyuA</i>	+ (57)	+ (60)	- (41)
19	<i>fimA2</i>	+ (47)	+ (82)	- (57)
20	<i>pabB</i>	+ (37)	+ (82)	+ (128)
21	<i>clpv non sakai</i>	- (0)	- (0)	- (49)
22	<i>ompT1</i>	+ (57)	+ (82)	+ (80)
23	<i>aec35</i>	- (0)	- (0)	- (36)
24	<i>ecpD1</i>	+ (46)	+ (82)	+ (129)
25	<i>ecpA1</i>	+ (46)	+ (82)	+ (129)
26	<i>ecpA2</i>	+ (46)	+ (82)	+ (129)

27	<i>astA</i>	- (2)	- (8)	- (52)
28	<i>papg allele II</i>	- (1)	- (31)	- (13)
29	<i>tsh</i>	+ (45)	+ (82)	+ (82)
30	<i>vat</i>	+ (45)	+ (82)	+ (82)
31	<i>sat2</i>	+ (38)	+ (64)	- (50)
32	<i>tia</i>	- (1)	- (31)	- (17)
33	<i>papA</i>	- (1)	- (30)	- (18)
34	<i>iutA1</i>	+ (50)	+ (57)	+ (122)
35	<i>clbN</i>	- (6)	- (0)	- (0)
36	<i>cldB</i>	- (6)	- (0)	- (0)
37	<i>iha</i>	+ (29)	+ (57)	- (50)
38	<i>cma</i>	- (28)	- (39)	- (36)
39	<i>csgA3</i>	- (0)	- (0)	- (7)

582 For each marker and each cluster, the table gives the most frequent result (+ for presence or – for absence) and the number in brackets is the number of  
583 isolates positive for the variable

584

585

586 **Table 4.** Characteristics of the three challenge strains selected for use in the pathogenicity experiment

Strain (cluster)	Origin of isolation*	Serogroup phylogroup and ST**	Virulence-associated genes detected by PCR or WGS***	Antimicrobial Resistance genes
19-381 (cluster 1)	pericardium	O50/O2:K1 :H5 B2 ST140	<i>aec4, chuA, celB2, csgA2, cvaC, ecpD1, ecpA, etsC, fimA, fepA3, frzorf4, <u>fyuA</u>, <u>hlyE</u>, <u>ibeA</u>, <u>ireA</u>, <u>iroN</u>, <u>irp2</u>, <u>iss</u>, <u>iucC</u>, <u>iutA</u>, <u>kpsE</u>, <u>mchF</u>, <u>neuC</u>, <u>nirC</u>, <u>ompT</u>, <u>pabB</u>, <u>phoB</u>, <u>rstA</u>, <u>sat2</u>, <u>sitA</u>, <u>terC</u>, <u>tkt1</u>, <u>traT</u>, <u>tsh</u>, <u>usp</u>, <u>vat</u>, <u>yfcv</u>, <u>YjjQ</u>, <u>YqiC</u></i>	<i>bla<sub>TEM-1B</sub>, tet(A), sul1, sul2, dfrA1, strA, strB, aadA1</i>
19-383-M1 (cluster 2)	liver	O24:H4 F ST117	<i>aec4, cea, celB2, chuA, <u>cmg</u>, <u>csgA1</u>, <u>cvaC</u>, <u>ecpD1</u>, <u>ecpA1</u>, <u>ecpA2</u>, <u>fimA</u>, <u>fepA3</u>, <u>frzorf4</u>, <u>fyuA</u>, <u>hlyE</u>, <u>iha</u>, <u>ireA</u>, <u>iroN</u>, <u>irp2</u>, <u>iss</u>, <u>lpfA</u>, <u>mchC</u>, <u>mchF</u>, <u>neuC</u>, <u>nirC</u>, <u>ompT</u>, <u>pabB</u>, <u>phoB</u>, <u>pic</u>, <u>rstA</u>, <u>sat2</u>, <u>sitA</u>, <u>terC</u>, <u>tkt1</u>, <u>traT</u>, <u>tsh</u>, <u>vat</u>, <u>YjjQ</u>, <u>YqiC</u></i>	<i>bla<sub>TEM-1B</sub>, tet(A), sul1, sul2, dfrA1, strB, strA, aadA1, mph(B), catA1</i>
19-385-M1 (cluster 3)	yolk	O86:H51 B1 ST155	<i>celB2, cia, cvaC, csgA1, ecpD1, ecpA1, ecpA2, etsC, ETT2, -fepC, fimA2, fepA3, hcp, <u>hlyE</u>, <u>ireA</u>, <u>iroN</u>, <u>iss</u>, <u>lpfA</u>, <u>mchF</u>, <u>nirC</u>, <u>ompT</u>, <u>pabB</u>, <u>phoB</u>, <u>papA-papG allele II</u>, <u>rstA</u>, <u>sat2</u>, <u>sitA</u>, <u>terC</u>, <u>tia</u>, <u>traT</u>, <u>YjjQ</u></i>	<i>tet(B), sul2</i>

587 \*origin of the strain or of its parental strain (organ from colibacillosis suffering chick); \*\*serogroup, sequence type (ST) and resistance genes determined by  
588 WGS and CGE server; \*\*\*detection by high-throughput PCR (Delannoy *et al.*, 2020) and/or virulence genes screened for using the CGE tool

589 Underlined genes were detected by PCR and WGS

590

591 **Table 5.** Pathogenicity experiment results: subcutaneous inoculation of three APEC strains (19-381, 19-383-M1 and 19-385-M1) to assess their virulence  
 592 (mortality and clinical status) in day-old chicks for two chicken breeds (Ross 308 and Leghorn).

Challenge strain	Breed	Group	Mortality <sup>a</sup> (%)	Clinical status (x,y,z) <sup>b</sup>								
				D1	D2	D3	D4	D5	D6	D7	D8	D9
Negative control	Ross 308	R-NI	0 <sup>A</sup>	0,0,0 <sup>A</sup> from D1 to D9								
	Leghorn	L-NI	0 <sup>D</sup>	0,0,0 <sup>C</sup> from D1 to D9								
19-381	Ross 308	R-381	100 <sup>C</sup>	No	Surviving	Chicks	from	D1	to	D9		
	Leghorn	L-381	100 <sup>F</sup>	6,0,0 <sup>C</sup>	1,3,1 <sup>C</sup>	0,0,1 <sup>C</sup>	No	surviving	chicks	From	D4 to	D9
19-383-M1	Ross 308	R-383M	84 <sup>B</sup>	13,3,0 <sup>B</sup>	7,7,0 <sup>B</sup>	4,8,1 <sup>B</sup>	4,3,3 <sup>B</sup>	3,1,2 <sup>A</sup>	4,0,0 <sup>A</sup>	4,0,0 <sup>A</sup>	4,0,0 <sup>A</sup>	4,0,0 <sup>A</sup>
	Leghorn	L-383M	52 <sup>E</sup>	19,1,0 <sup>D</sup>	16,3,1 <sup>D</sup>	15,5,1 <sup>D</sup>	13,3,1 <sup>D</sup>	11,2,3 <sup>C</sup>	12,1,0 <sup>C</sup>	12,0,0 <sup>C</sup>	12,0,0 <sup>C</sup>	12,0,0 <sup>C</sup>
19-385-M1	Ross 308	R-385M	0 <sup>A</sup>	0,0,0 <sup>A</sup> from D1 to D9								
	Leghorn	L-385M	0 <sup>D</sup>	0,0,0 <sup>C</sup> from D1 to D9								

593

594 a comparisons were carried out within each chicken breed. In this column, percentages with different superscripts (A, B, C for the Ross 308 and D, E, F for Leghorn) are significantly different (p<0.05)

595 b (x,y,z) for each study day corresponds to the number of chicks that were scored 0, 1 or 2 (respectively normal, slightly depressed, prostrate). From D1 to D9, each inoculated breed was compared with the corresponding  
 596 negative control group (A, B for the Ross 308 and C, D for Leghorn). For a given chicken breed, the clinical status score distributions with different superscripts are significantly different (p<0.05)

597

598

599

600

601

602

603

604 **Table 6.** Evaluation of the protection of day-old chicks against an *E. coli* homologous challenge via the passive immunization conferred by their autogenous  
 605 vaccinated mother hens. The autogenous vaccine, inactivated and adjuvanted, was prepared from *E. coli* strains 19-381 and 19-383-M1.

Group	Mortality <sup>a</sup> (%)	Clinical status <sup>b</sup>								
		D1	D2	D3	D4	D5	D6	D7	D8	D9
Negative control	0 <sup>A</sup>	0,0,0 from D1 to D9								
Non-vaccinated and challenged 19-381	90 <sup>D</sup>	4,13,0	3,1,0	3,1,0	3,0,1	3,0,0	3,0,0	3,0,0	3,0,0	3,0,0
Non-vaccinated and challenged 19-383-M1	80 <sup>B</sup>	7,13,0	5,0,0	4,0,0	4,0,0	4,0,0	4,0,0	4,0,0	4,0,0	4,0,0
Vaccine Control	0 <sup>A</sup>	0,0,0 from D1 to D9								
Vaccinated and challenged 19-381	95 <sup>D</sup>	2,15,1	1,1,0	1,1,0	1,1,0	1,0,0	No surviving chicks from D6 to D9			
Vaccinated and challenged 19-383-M1	40 <sup>C</sup>	16,4,0	15,0,0	14,0,0	12,0,0	12,0,0	12,0,0	12,0,0	12,0,0	12,0,0

606 a comparisons were carried out within each APEC strain (grey line for 19-381 and bold line for 19-383-M1). In this column, percentages in compared groups with different superscripts are significantly different (p<0.05)

607 b (x,y,z) for each study day corresponds to the number of chicks that were scored 0, 1 or 2 (respectively normal, slightly depressed, prostrate).

608




Figure 1: Dendrogram obtained by hierarchical clustering of 268 *E. coli* strains (x-labels) from 45 variables (i.e. phylogroup markers, serogroups and 66 virulence markers). These variables are used to calculate the distances between the 268 strains (y-labels).




Figure 2: Mortality rate over time after challenge with the *E. coli* 19-383-M1 strain in non-vaccinated (NVC) and vaccinated (VC) chicks